XML 41 R21.htm IDEA: XBRL DOCUMENT
v3.19.1

Business Segment Information | 12 Months Ended
--- | ---
Mar. 31, 2019
Notes To Financial Statements [Abstract] |
Business Segment Information | . Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs. Linen Management Services were divested in fiscal 2017. Our Life Sciences segment offers consumable products, equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and capital equipment. Our Applied Sterilization Technologies segment offers contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. In fiscal 2019, we ceased the allocation of certain corporate costs to our segments to align with internal management measures. The prior period operating income measures have been recast for comparability. For the year ended March 31, 2019, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues.
Years Ended March 31, |  | 2019 |  | 2018 |  | 2017
Revenues: |  |  |  |  |  |
Healthcare Products |  | $ | 1,338,428 |  |  | $ | 1,276,054 |  |  | $ | 1,266,517 |
Healthcare Specialty Services |  | 510,057 |  |  | 469,065 |  |  | 539,536 |
Life Sciences |  | 378,558 |  |  | 361,590 |  |  | 328,866 |
Applied Sterilization Technologies |  | 555,127 |  |  | 513,287 |  |  | 477,837 |
Total revenues |  | $ | 2,782,170 |  |  | $ | 2,619,996 |  |  | $ | 2,612,756 |
Operating income (loss): |  |  |  |  |  |
Healthcare Products |  | 323,684 |  |  | 294,162 |  |  | 285,177 |
Healthcare Specialty Services |  | 64,222 |  |  | 58,458 |  |  | 41,019 |
Life Sciences |  | 132,129 |  |  | 123,889 |  |  | 109,953 |
Applied Sterilization Technologies |  | 221,828 |  |  | 196,297 |  |  | 176,397 |
Total reportable segments |  | 741,863 |  |  | 672,806 |  |  | 612,546 |
Corporate |  | (184,900 | ) |  | (162,999 | ) |  | (137,403 | )
Total operating income before adjustments |  | $ | 556,963 |  |  | $ | 509,807 |  |  | $ | 475,143 |
Less: Adjustments |  |  |  |  |  |
Goodwill impairment loss (1) |  | — |  |  | — |  |  | 58,356 |
Amortization of inventory and property "step up" to fair value (2) |  | 2,440 |  |  | 1,599 |  |  | 4,743 |
Amortization of acquired intangible assets (2) |  | 86,878 |  |  | 67,793 |  |  | 66,398 |
Acquisition and integration related transaction charges (3) |  | 8,901 |  |  | 16,211 |  |  | 30,082 |
(Gain) loss on fair value adjustment of acquisition related contingent consideration |  | (842 | ) |  | (593 | ) |  | 2,569 |
Net (gain) loss on divestiture of businesses (2) |  | (1,370 | ) |  | 14,547 |  |  | 86,574 |
Impact of the U.S. Tax Cuts and Jobs Act (4) |  | — |  |  | 10,264 |  |  | — |
Redomiciliation costs (5) |  | 8,783 |  |  | — |  |  | — |
Restructuring charges (6) |  | 40,708 |  |  | 103 |  |  | 215 |
Total operating income |  | $ | 411,465 |  |  | $ | 399,883 |  |  | $ | 226,206 |
(1) For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets". (2) For more information regarding our recent acquisitions and divestitures see Note 18 titled, "Business Acquisitions and Divestitures". Amortization of purchased intangible assets fiscal 2019 total includes an impairment charge of $16,249, see Note 3 titled, "Goodwill and Intangible Assets", for more information. (3) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (4) Represents a one-time special employee bonus paid to most U.S. employees and associated professional fees. (5) Costs incurred in connection with the decision to redomicile. (6) See Note 2 titled, "Restructuring", for more information. Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare Products and Life Sciences segments. Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare Products and Life Sciences segments. Therefore, their respective amounts are reported together.
March 31, |  | 2019 |  | 2018
Assets: |  |  |  |
Healthcare Products and Life Sciences |  | $ | 1,611,852 |  |  | $ | 1,621,156 |
Healthcare Specialty Services |  | 805,349 |  |  | 813,909 |
Applied Sterilization Technologies |  | 2,655,870 |  |  | 2,765,269 |
Total assets |  | $ | 5,073,071 |  |  | $ | 5,200,334 |
Years Ended March 31, |  | 2019 |  | 2018 |  | 2017
Capital Expenditures |  |  |  |  |  |
Healthcare Products and Life Sciences |  | $ | 49,688 |  |  | $ | 52,767 |  |  | $ | 39,253 |
Healthcare Specialty Services |  | 39,950 |  |  | 16,497 |  |  | 42,408 |
Applied Sterilization Technologies |  | 100,077 |  |  | 96,193 |  |  | 91,240 |
Total Capital Expenditures |  | $ | 189,715 |  |  | $ | 165,457 |  |  | $ | 172,901 |
Depreciation, Depletion, and Amortization |  |  |  |  |  |
Healthcare Products and Life Sciences (1) |  | $ | 81,264 |  |  | $ | 52,025 |  |  | $ | 46,709 |
Healthcare Specialty Services |  | 33,392 |  |  | 29,269 |  |  | 56,860 |
Applied Sterilization Technologies (1) |  | 111,265 |  |  | 97,038 |  |  | 84,573 |
Total Depreciation, Depletion, and Amortization |  | $ | 225,921 |  |  | $ | 178,332 |  |  | $ | 188,142 |
(1) The fiscal 2019 totals include the impact of Restructuring and an impairment charge. See Note 2 titled, "Restructuring" and Note 3 titled, "Goodwill and Intangible Assets", for additional information. Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each geographic area.
March 31, |  | 2019 |  | 2018
Property, Plant, and Equipment, Net |  |  |  |
Ireland |  | $ | 41,137 |  |  | $ | 38,946 |
United States |  | 577,113 |  |  | 530,591 |
Other locations |  | 413,332 |  |  | 440,987 |
Property, Plant, and Equipment, Net |  | $ | 1,031,582 |  |  | $ | 1,010,524 |
Years Ended March 31, |  | 2019 |  | 2018 |  | 2017
Revenues: |  |  |  |  |  |
Ireland |  | $ | 56,784 |  |  | $ | 48,246 |  |  | $ | 42,733 |
United States |  | 1,976,814 |  |  | 1,836,414 |  |  | 1,803,457 |
Other locations |  | 748,572 |  |  | 735,336 |  |  | 766,566 |
Total Revenues |  | $ | 2,782,170 |  |  | $ | 2,619,996 |  |  | $ | 2,612,756 |
Years Ended March 31, |  | 2019 |  | 2018 |  | 2017
Healthcare Products: |  |  |  |  |  |
Capital equipment |  | $ | 568,811 |  |  | 527,402 |  | 549,238
Consumables |  | 414,969 |  |  | 412,495 |  | 403,747
Service |  | 354,648 |  |  | 336,157 |  |  | 313,532 |
Total Healthcare Products Revenues |  | $ | 1,338,428 |  |  | $ | 1,276,054 |  |  | $ | 1,266,517 |
Total Healthcare Specialty Services Revenues |  | $ | 510,057 |  |  | $ | 469,065 |  |  | $ | 539,536 |
Life Sciences: |  |  |  |  |  |
Capital equipment |  | $ | 102,714 |  |  | 100,555 |  | 84,069
Consumables |  | 161,780 |  |  | 150,656 |  | 143,143
Service |  | 114,064 |  |  | 110,379 |  | 101,654
Total Life Sciences Revenues |  | $ | 378,558 |  |  | $ | 361,590 |  |  | $ | 328,866 |
Applied Sterilization Technologies Service Revenues |  | $ | 555,127 |  |  | $ | 513,287 |  |  | $ | 477,837 |
Total Revenues |  | $ | 2,782,170 |  |  | $ | 2,619,996 |  |  | $ | 2,612,756 |

X
- Definition Notes to Financial Statements [Abstract] + References No definition available. + Details
Name: | ste_NotesToFinancialStatementsAbstract
Namespace Prefix: | ste_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration